Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN cut its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,367 shares of the medical technology company's stock after selling 27,759 shares during the quarter. Wells Fargo & Company MN owned about 0.07% of Alphatec worth $903,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Alphatec by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after purchasing an additional 47,797 shares during the last quarter. American Century Companies Inc. boosted its stake in Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after buying an additional 1,334,780 shares during the last quarter. Geode Capital Management LLC grew its holdings in Alphatec by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock valued at $21,919,000 after buying an additional 24,283 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of Alphatec by 112.4% in the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock worth $13,366,000 after acquiring an additional 770,586 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Alphatec by 21.2% during the 4th quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company's stock worth $11,037,000 after acquiring an additional 210,519 shares during the period. Hedge funds and other institutional investors own 66.35% of the company's stock.

Alphatec Trading Up 8.5 %

NASDAQ:ATEC traded up $0.94 during trading hours on Friday, reaching $12.00. 4,701,141 shares of the stock were exchanged, compared to its average volume of 2,070,936. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $13.79. The business has a 50-day moving average of $10.46 and a two-hundred day moving average of $9.89. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -9.38 and a beta of 1.20. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The firm had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business's revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.34) earnings per share. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Piper Sandler reissued an "overweight" rating and issued a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research note on Friday. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research report on Friday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Alphatec currently has an average rating of "Moderate Buy" and an average price target of $17.89.

Insider Activity

In other news, CEO Patrick Miles sold 43,459 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $11.95, for a total value of $519,335.05. Following the sale, the chief executive officer now directly owns 6,065,772 shares in the company, valued at approximately $72,485,975.40. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Sponsel sold 36,256 shares of Alphatec stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the transaction, the executive vice president now owns 735,074 shares of the company's stock, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 222,113 shares of company stock valued at $2,519,725. 22.80% of the stock is currently owned by company insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.